Evidence map›Paper›PMID 38730598›Full record

ReviewCancers2024

Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy.

Sophia J Zhao, Daniel Prior, Christine M Heske, Juan C Vasquez

Abstract readReview
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sophia J ZhaoDepartment of Pediatric Hematology/Oncology, Yale University School of Medicine, New Haven, CT 06510, USA.ORCID 0009-0008-6914-3583
Daniel PriorDepartment of Pediatric Hematology/Oncology, Yale University School of Medicine, New Haven, CT 06510, USA.
Christine M HeskePediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-0956-6249
Juan C VasquezDepartment of Pediatric Hematology/Oncology, Yale University School of Medicine, New Haven, CT 06510, USA.ORCID 0000-0002-9031-7639

Funding

Development and translation of novel therapies for pediatric sarcomaZIABC011774 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HESKE, CHRISTINE · 2017 to 2025
$9.3M
Targeting the DNA damage response with PARP and ATR inhibition to potentiate cytotoxicity and improve efficacy of immune checkpoint blockade in IDH mutant gliomasK08CA258796 · NCI · YALE UNIVERSITY · PI VASQUEZ, JUAN C · 2021 to 2025
$1.2M
NCI NIH HHS K08 CA258796
6 · The paper itself

Abstract

DNA damage is fundamental to tumorigenesis, and the inability to repair DNA damage is a hallmark of many human cancers. DNA is repaired via the DNA damage repair (DDR) apparatus, which includes five major pathways. DDR deficiencies in cancers give rise to potential therapeutic targets, as cancers harboring DDR deficiencies become increasingly dependent on alternative DDR pathways for survival. In this review, we summarize the DDR apparatus, and examine the current state of research efforts focused on identifying vulnerabilities in DDR pathways that can be therapeutically exploited in pediatric extracranial solid tumors. We assess the potential for synergistic combinations of different DDR inhibitors as well as combinations of DDR inhibitors with chemotherapy. Lastly, we discuss the immunomodulatory implications of targeting DDR pathways and the potential for using DDR inhibitors to enhance tumor immunogenicity, with the goal of improving the response to immune checkpoint blockade in pediatric solid tumors. We review the ongoing and future research into DDR in pediatric tumors and the subsequent pediatric clinical trials that will be critical to further elucidate the efficacy of the approaches targeting DDR.

Indexed as

DNA damage responseEwing sarcomaimmune checkpoint inhibitionneuroblastomaosteosarcomapediatric extracranial solid tumorsrhabdomyosarcomasynthetic lethality

Identifiers

PMID38730598
PMCPMC11083679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.